Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma

Timothy F. Cloughesy(University of California, Los Angeles), Michael A. Vogelbaum(Moffitt Cancer Center), Derek Ostertag, Tobias Walbert(Henry Ford Health System), Tiffany T. Montellano(Kura Oncology (United States)), Clark C. Chen(Brown University), Daniela A. Bota(University of California, Irvine), Steven Brem(University of Pennsylvania), David Cachia(University of Massachusetts Chan Medical School), William P. Accomando(Retriev Technologies (United States)), Daniel J. Hogan(Retriev Technologies (United States)), Jay‐Jiguang Zhu(The University of Texas Health Science Center at Houston), Thian Kheoh(Janssen (United States)), David Piccioni(Center for Personalized Cancer Treatment), Lyndon Kim(Icahn School of Medicine at Mount Sinai), Chetan Bettegowda(Johns Hopkins University), Joseph Landolfi(Hackensack Meridian Health), Dimitris G. Placantonakis(New York University), Yaron A. Moshel(Overlook Medical Center), Aliz R. Rao(BioNano Genomics (United States)), Fábio M. Iwamoto(Columbia University), Nicholas Butowski(University of California, San Francisco), James Perry, Denise Damek(University of Colorado Anschutz Medical Campus), Michael Salacz(The University of Kansas Cancer Center), George Kaptain(Hackensack University Medical Center), Brad Elder(The Ohio State University), Fairooz F. Kabbinavar(Kaiser Permanente), Harry E. Gruber, Kevin Petrecca(McGill University Health Centre)
JAMA Oncology
October 29, 2020
Cited by 141


Related Papers